Our carefully selected partners and affiliates follow our core values — celebrating the potential of animal models whilst respecting all living things. They help us to work towards our vision of aiding the development of the population’s health through the application of our leading humanized liver, chimeric mouse model.
PhoenixBio is linked with many academic partners (University of Southern California), CRO partners, and affiliates (CMHL Consortium).
The Saito Lab
Funded research by PhoenixBio for the humanized liver chimeric mouse research program.
Principle Investigator: Takeshi Saito, M.D., Ph.D., Associate Professor of Medicine, Division of Gastrointestinal and Liver Diseases, Molecular Microbiology & Immunology, and Pathology. Keck School of Medicine of the University of Southern California.
Axcelead Drug Discovery Partners, Inc.
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Axcelead Drug Discovery Partners, Inc. is the first comprehensive drug discovery solution provider in the Japanese pharmaceutical industry. They began operating on July 1, 2017 and took over part of the drug discovery research division of Takeda Pharmaceutical Company Limited.
Axcelead has deep expertise in non-clinical drug discovery research with abundant technology, knowledge, and experience in a wide range of disease areas. Experienced in working with a wide variety of domestic and foreign players involved in drug creation, they provide a one-stop shop, offering tailored services to meet the client’s needs, from initial exploratory research to optimization of candidate compounds to the process of bridging to clinical development.
LSIM Safety Institute Corporation
Address: Headquarters: 13-4, Uchikanda 1-chome, Chiyoda-ku Tokyo; Kumamoto Laboratory: 1285, Kurisaki-machi, Uto-shi, Kumamoto 869-0425, Japan
As a company contributing to "National Health and Medical Strategy", LSIM Safety Institute conducts various safety studies including high-level pharmacological efficacy and pharmacokinetic studies for application for regulatory approval. Their facility is thoroughly equipped and has been audited and certified for pharmaceutical, medical device, cellular and tissue-based product, agricultural chemical, and Chemical Substances Control Law GLPs. In addition to pharmaceuticals and cellular and tissue-based products, LSIM Safety Institute’s expertise lies in contract testing services for the development of food products (food additives and FOSHU products, etc.), new chemical substances, and agricultural chemicals, as well as preparation of application documents and provision of laboratory technique education.
Address: 2701 Kent Avenue, West Lafayette, IN 47906 USA
Inotiv, Inc., provides drug discovery and development services and analytical instruments that help pharmaceutical, biotechnology, leading academic institutions and government organizations in their drug development and research efforts. Inotiv’s mission is to provide drug developers with superior scientific research and innovative analytical instrumentation, which saves time, money, and lives, to bring revolutionary new drugs to market quickly and safely. Inotiv strives to provide services that will generate high-quality and timely data in support of new drug approval or use expansion.
InterVivo Solutions, Inc.
Address: 120 Carlton St Suite 203, Toronto, ON M5A 4K2, Canada
InterVivo Solutions aims to improve the clinical success of new drugs by providing translational models and transformative research services. We achieve this goal by providing clinically relevant animal models of disease and drug disposition in multiple species, access to state-of-the-art tools and techniques, and expertise in adding value to pre-clinical drug assets and drug discovery programs.
Shin Nippon Biomedical Laboratories, Ltd.
Address: Head Office: St Luke's Tower 28F, 8-1 Akashi-cho, Chuo-ku, Tokyo,104-0044, Japan; Kagoshima Main Branch, Drug Safety Research Laboratories: 2438 Miyanoura, Kagoshima, 891-1394, Japan
Shin Nippon Biomedical Laboratories (SNBL Japan), was founded in Kagoshima as Japan’s first contract research organization in 1957. Since then, SNBL has steadily expanded and innovated to become a global business that works in the pre-clinical research, clinical pharmacology research, pharmacokinetics and analysis, clinical trial, site management organization (SMO), and other industries.
Sekisui Medical Co., Ltd.
Address: Urban Net Nihonbashi 2-chome Building, Nihonbashi 2-1-3, Chuo-ku, Tokyo 103-0027 Japan
Sekisui Medical Co., Ltd’s Drug Development Solutions Centre was established in May 1965 in Tokai Japan, Ibaraki prefecture, for the purpose of contributing to the progress and expansion of academic research. During this 50-year period, Sekisui Medical has worked tirelessly to support new drug development, mainly in the field of non-clinical pharmacokinetic studies using radio labelled compounds as well as new technologies dictated by contemporary needs, satisfying our customers. Sekisui Medical will further expand their responsibility as a R&D type contract research organization by bridging animal and human research within pharmaceutical drug development.
Hamri Co., Ltd.
Address: 2638-2, Osaki, Koga City, Ibaraki Prefecture 306-0101
Hamri Co., Ltd. is a contract facility that carries out non-clinical tests such as pharmacological, safety, and dynamic tests of various developed products (foods, medical devices / instruments, pesticides, etc.) including pharmaceuticals. Hamri has abundant experience in drug efficacy and pharmacological testing in infection / anticancer tests, sleep tests, implantation tests, and more. Hamri has specialized facilities to support a wide range of infection tests using various viruses, bacteria, and fungi.
The CMHL Consortium
The CMHL Consortium was founded in 2016 to more fully evaluate the humanized liver chimeric mouse model (the PXB-mouse®) for DMPK and toxicology applications, primarily in relation to the discovery and development of new therapeutics. Since then, the Consortium has expanded to include applications of the PXB-mouse® in areas such as oligonucleotide therapeutics and NASH, as well as characterization of PXB-cells — the hepatocytes freshly isolated from the PXB-mouse®. The consortium consists of 10 industry collaborators from pharmaceutical and biotech companies and 1 academic associate collaborator.